In advanced NSCLC with an EGFR mutation, the combination of apatinib, a VEGFR inhibitor, with gefitinib, a first-generation EGFR tyrosine kinase inhibitor (TKI), may extend the mPFS for 19.2 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.